Lebrikizumab in Moderate-to-severe Atopic Dermatitis

NCT06906497 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: lebrikizumab

Sponsor

Johann E Gudjonsson MD PhD

Collaborators

[object Object]
[object Object]